All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Cyclin-dependent kinase (CDK) pathways are often dysregulated in AML. CDKs control cell-cycle progression and gene transcription. Inhibiting CDKs can lead to downregulation of cell survival genes which are regulated by MCL-1, MYC, and cyclin D1. CDK9 is one target of therapeutic agents in AML. CDK inhibitors such as alvocidib, dinaciclib, and TG02 are in clinical development.